Multicenter evaluation of abbreviated MRI and ultrasound for detecting early-stage hepatocellular carcinoma.
| Title: | Multicenter evaluation of abbreviated MRI and ultrasound for detecting early-stage hepatocellular carcinoma. |
|---|---|
| Authors: | Seif El Dahan K; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.; Yokoo T; Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA.; Daher D; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.; Davenport MS; Department of Radiology, University of Michigan, Ann Arbor, MI, USA.; Department of Urology, University of Michigan, Ann Arbor, MI, USA.; Fetzer DT; Department of Radiology, UT Southwestern Medical Center, Dallas, TX, USA.; Mendiratta-Lala M; Department of Radiology, University of Michigan, Ann Arbor, MI, USA.; Rich NE; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA.; Yang E; Division of Gastroenterology, Kaiser Permanente Medical Group, Riverside, CA, USA.; Parikh ND; Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA.; Singal AG; Department of Internal Medicine, UT Southwestern Medical Center, Dallas, TX, USA. |
| Source: | JHEP reports : innovation in hepatology [JHEP Rep] 2025 Feb 12; Vol. 7 (5), pp. 101357. Date of Electronic Publication: 2025 Feb 12 (Print Publication: 2025). |
| Publication Type: | Journal Article |
| Language: | English |
| Journal Info: | Publisher: Elsevier B.V Country of Publication: Netherlands NLM ID: 101761237 Publication Model: eCollection Cited Medium: Internet ISSN: 2589-5559 (Electronic) Linking ISSN: 25895559 NLM ISO Abbreviation: JHEP Rep Subsets: PubMed not MEDLINE |
| Imprint Name(s): | Original Publication: [Amsterdam] : Elsevier B.V., [2019]- |
| Abstract: | Background & Aims: Abbreviated MRI (AMRI) has been proposed as an alternative to ultrasound for hepatocellular carcinoma (HCC) surveillance; however, comparative data for AMRI and ultrasound are needed. Thus, we evaluated the sensitivity and specificity of dynamic contrast-enhanced (DCE)-AMRI and ultrasound for early-stage HCC detection in patients with cirrhosis.; Methods: We conducted a multicenter retrospective case-control study among patients with cirrhosis (cases with early-stage HCC as per Milan Criteria; controls without HCC) who underwent an ultrasound and a DCE-MRI within a 6-month period between 2012 and 2019. HCC diagnosis was confirmed by imaging alone in 85% and by histopathology in 15% of patients. Dynamic AMRI examinations were simulated from the full MRI by selecting relevant sequences. Independent, blinded interpretations of ultrasounds and AMRI results were performed using Liver Imaging Reporting and Data System algorithms. Ultrasounds were considered positive if US-3 observations were detected. AMRI was considered positive if LR-4, LR-5, or LR-M were detected. Per-patient sensitivity and specificity for early-stage HCC detection were estimated, and cross-modality differences were tested.; Results: We included 216 cases and 432 controls. Patient-level sensitivity and specificity of AMRI were significantly higher compared with ultrasound: 80.1% (95% CI 76.1-83.6) vs. 71.1% (95% CI 66.6-75.2), p |
| Competing Interests: | AGS has served as a consultant or on advisory boards for Bayer, FujiFilm Medical Sciences, Exact Sciences, Universal Dx, Glycotest, Roche, Freenome, Delfi, GRAIL, Genentech, AstraZeneca, Eisai, Exelixis, Boston Scientific, HistoSonics. NDP has served as a consultant or on advisory boards for Bayer, FujiFilm Medical Sciences, Exact Sciences, Glycotest, and Freenome. MSD is a consultant for Covera Health, treasurer for the Society of Advanced Body Imaging, and receives royalties from Wolters Kluwer. NER has served as consultant for AstraZeneca. DTF has served on the advisor board for GE HealthCare and Philips Healthcare, and has active research agreements with GE HealthCare, Philips Healthcare, and Siemens Healthineers. TY has served on an advisory board of Guerbet and speaker panels for Siemens Healthineers and Northwest Imaging, as well as active research agreements with Siemens Healthineers. The remaining authors declare no conflicts of interest that pertain to this work. Please refer to the accompanying ICMJE disclosure forms for further details. |
| References: | Gastroenterology. 2021 Jun;160(7):2572-2584. (PMID: 33705745); Clin Transl Gastroenterol. 2017 Jun 22;8(6):e101. (PMID: 28640287); Dig Dis Sci. 2014 Dec;59(12):3073-7. (PMID: 25027206); Liver Transpl. 2022 Dec;28(12):1865-1875. (PMID: 35980600); JAMA Netw Open. 2021 Apr 1;4(4):e214708. (PMID: 33825840); Hepatol Commun. 2023 Mar 7;7(3):. (PMID: 36881615); Clin Gastroenterol Hepatol. 2023 Apr;21(4):1091-1093.e3. (PMID: 34902571); CA Cancer J Clin. 2007 Mar-Apr;57(2):75-89. (PMID: 17392385); Am J Gastroenterol. 2024 Nov 1;119(11):2251-2258. (PMID: 38686922); Am J Epidemiol. 2014 Jan 15;179(2):226-35. (PMID: 24114655); Hepatology. 2024 Jan 1;79(1):107-117. (PMID: 37401857); J Natl Cancer Inst. 2001 Jul 18;93(14):1054-61. (PMID: 11459866); Ann Surg Oncol. 2014 Apr;21(4):1287-95. (PMID: 24318095); Gastroenterology. 2019 Mar;156(4):976-986. (PMID: 30445016); Liver Cancer. 2020 Sep;9(5):503-517. (PMID: 33083277); Eur Radiol. 2020 Aug;30(8):4147-4149. (PMID: 32394280); Clin Gastroenterol Hepatol. 2021 Sep;19(9):1925-1932.e1. (PMID: 32920214); Aliment Pharmacol Ther. 2022 Mar;55(6):683-690. (PMID: 35170052); Clin Gastroenterol Hepatol. 2024 Apr;22(4):760-767.e1. (PMID: 37544418); Gastroenterology. 2019 Nov;157(5):1253-1263.e2. (PMID: 31374215); Korean J Radiol. 2022 Jun;23(6):598-614. (PMID: 35434979); Aliment Pharmacol Ther. 2017 Jan;45(1):169-177. (PMID: 27862091); Gut. 2021 Feb;70(2):401-407. (PMID: 32398224); J Hepatol. 2023 Jan;78(1):207-216. (PMID: 36089157); J Hepatol. 2022 Apr;76(4):981-982. (PMID: 34762998); JAMA Oncol. 2017 Apr 01;3(4):456-463. (PMID: 27657493); Am J Gastroenterol. 2006 Mar;101(3):513-23. (PMID: 16542288); J Hepatol. 2022 Mar;76(3):681-693. (PMID: 34801630); Clin Gastroenterol Hepatol. 2024 Feb;22(2):295-304.e2. (PMID: 37573986); Hepatology. 2023 Dec 1;78(6):1922-1965. (PMID: 37199193); J Hepatol. 2021 Jul;75(1):108-119. (PMID: 33548385); Gastroenterology. 2018 May;154(6):1706-1718.e1. (PMID: 29425931); Clin Gastroenterol Hepatol. 2022 Jan;20(1):204-215.e6. (PMID: 33618022); Nat Rev Clin Oncol. 2023 Dec;20(12):864-884. (PMID: 37884736); Abdom Radiol (NY). 2018 Jan;43(1):41-55. (PMID: 28936543); J Hepatol. 2018 Jul;69(1):182-236. (PMID: 29628281); EClinicalMedicine. 2024 Aug 13;75:102755. (PMID: 39234558); Radiographics. 2020 Nov-Dec;40(7):1916-1931. (PMID: 33136476); Radiology. 2023 Apr;307(2):e220917. (PMID: 36692401); Clin Gastroenterol Hepatol. 2022 Jul;20(7):1561-1569.e4. (PMID: 34119640); Hepatology. 2021 Feb;73(2):713-725. (PMID: 32383272); Clin Gastroenterol Hepatol. 2021 May;19(5):987-995.e1. (PMID: 32629122); Liver Int. 2022 Aug;42(9):2080-2092. (PMID: 34817921); Biometrics. 1977 Mar;33(1):159-74. (PMID: 843571); Hepatol Commun. 2021 Sep;5(9):1481-1489. (PMID: 34510836); Hepatology. 2017 Apr;65(4):1196-1205. (PMID: 27775821); AJR Am J Roentgenol. 2022 Jun;218(6):1010-1020. (PMID: 34910539); J Hepatol. 2024 Sep;81(3):461-470. (PMID: 38636849) |
| Contributed Indexing: | Keywords: Abbreviated MRI; Cirrhosis; Hepatocellular carcinoma; Surveillance; Ultrasound |
| Entry Date(s): | Date Created: 20250505 Latest Revision: 20250507 |
| Update Code: | 20260130 |
| PubMed Central ID: | PMC12048809 |
| DOI: | 10.1016/j.jhepr.2025.101357 |
| PMID: | 40321196 |
| Database: | MEDLINE |
Journal Article